Bli medlem
Bli medlem

Du är här


Probi: Probi secures strategic US order

Probi has secured a major order valued at MSEK 3.6 from the US
self-care product company Pharmavite. The order pertains to the
dietary supplement Probi Digestis®, which promotes gastrointestinal
health. The order is based on strong demand for Probi's digestive
health capsules in US pharmacies and retail stores. The order
consisting of a number of part shipments will be delivered during the
second and third quarter of 2014.

This is one of the largest orders ever received by Probi in the
Consumer Healthcare business area.

"Our partnership with Pharmavite has been expanded over the past year.
We highly value Pharmavite's confidence in our products. Our
assessment is that we have a continued strong development in the
North American market ahead of us," says Peter Nählstedt, CEO of

Pharmavite launched Probi's digestive health capsules in the US market
in 2012 and they have accounted for a significant portion of Probi's
growth in the US. The digestive health capsules, marketed under the
Nature Made®brand, are Probi's dietary supplement Probi Digestis® and
are based on the company's well-documented probiotic strain
Lactobacillus plantarum 299v (DSM 9843).

Pharmavite operates in the self-care market niche and has been active
in the US market for more than 40 years. The company markets and
sells vitamins, minerals, dietary supplements and health food
products under well-known brands such as Nature Made® and SOYJOY®.
Pharmavite is based in Northridge, California, and is a subsidiary of
the global pharmaceutical company Otsuka Pharmaceutical.

In addition to Pharmavite, Probi has well-established partnerships
with the probiotics specialist Viva 5 Corporation and the healthcare
product company Wakunaga, as well as NextFoods in the Functional Food

Peter Nählstedt, CEO, Probi, tel: +46 46 286 89 23 or mobile +46 723
86 99 83, e-mail:

Niklas Bjärum, VP Marketing & Sales, tel +46 46 286 89 67 or mobile
+46 705 38 88 64, e-mail:

Probi AB is a Swedish publicly traded biotechnology company that
develops effective and well-documented probiotics. Through its
research, Probi has created a strong product portfolio in the
gastrointestinal health and immune system areas. The products are
available to consumers in more than 30 countries worldwide. The
customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments.
Probi had sales of MSEK 102 in 2013. The Probi share is listed on
NASDAQ OMX Stockholm, Small-cap. Probi has approximately 4,000
shareholders.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.